This company listing is no longer active
NVN Liquidation Past Earnings Performance
Past criteria checks 0/6
NVN Liquidation has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 512.7% per year.
Key information
6.1%
Earnings growth rate
29.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 512.7% |
| Return on equity | n/a |
| Net Margin | -128.6% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)
Jun 07
Novan Q2 2022 Earnings Preview
Aug 10Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition
Jul 19Novan shares under pressure after proposing capital raise
Jun 16Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health
Jun 07Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech
Apr 28Novan regains Nasdaq compliance for minimum bid price requirement
Jan 29Novan EPS in-line, beats on revenue
Oct 30Revenue & Expenses Breakdown
How NVN Liquidation makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 25 | -32 | 38 | 0 |
| 31 Dec 22 | 24 | -31 | 34 | 0 |
| 30 Sep 22 | 14 | -37 | 31 | 0 |
| 30 Jun 22 | 9 | -37 | 26 | 0 |
| 31 Mar 22 | 4 | -34 | 16 | 0 |
| 31 Dec 21 | 3 | -30 | 12 | 0 |
| 30 Sep 21 | 3 | -28 | 11 | 0 |
| 30 Jun 21 | 4 | -30 | 11 | 0 |
| 31 Mar 21 | 5 | -32 | 11 | 0 |
| 31 Dec 20 | 5 | -29 | 11 | 0 |
| 30 Sep 20 | 5 | -29 | 11 | 3 |
| 30 Jun 20 | 5 | -30 | 10 | 7 |
| 31 Mar 20 | 5 | -30 | 10 | 11 |
| 31 Dec 19 | 5 | -30 | 10 | 15 |
| 30 Sep 19 | 8 | -17 | 11 | 15 |
| 30 Jun 19 | 7 | -15 | 12 | 15 |
| 31 Mar 19 | 6 | -14 | 12 | 15 |
| 31 Dec 18 | 6 | -13 | 12 | 15 |
| 30 Sep 18 | 3 | -28 | 11 | 15 |
| 30 Jun 18 | 3 | -28 | 11 | 15 |
| 31 Mar 18 | 3 | -30 | 12 | 11 |
| 31 Dec 17 | 3 | -37 | 13 | 14 |
| 30 Sep 17 | 2 | -42 | 14 | 13 |
| 30 Jun 17 | 1 | -52 | 14 | 11 |
| 31 Mar 17 | 0 | -60 | 14 | 13 |
| 31 Dec 16 | 0 | -60 | 13 | 9 |
| 30 Sep 16 | 0 | -57 | 13 | 8 |
| 30 Jun 16 | 0 | -45 | 13 | 7 |
| 31 Mar 16 | 0 | -32 | 11 | 6 |
| 31 Dec 15 | 0 | -26 | 9 | 5 |
| 30 Sep 15 | -3 | -21 | 7 | 2 |
| 31 Dec 14 | 0 | -13 | 5 | 2 |
| 31 Dec 13 | 3 | -6 | 4 | 3 |
Quality Earnings: NOVN.Q is currently unprofitable.
Growing Profit Margin: NOVN.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NOVN.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NOVN.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOVN.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: NOVN.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/01 22:05 |
| End of Day Share Price | 2024/05/01 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NVN Liquidation, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Oren Livnat | H.C. Wainwright & Co. |